The estimated Net Worth of Prondzynski Heino Von is at least $499 Mille dollars as of 31 January 2023. Mr. Von owns over 1,004 units of Quotient Ltd stock worth over $4,401 and over the last 10 years he sold QTNT stock worth over $29,500. In addition, he makes $465,440 as Independent Chairman of the Board at Quotient Ltd.
Sign up
Mr. Prondzynski QTNT stock SEC Form 4 insiders trading
Heino has made over 25 trades of the Quotient Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,004 units of QTNT stock worth $382 on 31 January 2023.
The largest trade he's ever made was buying 700,000 units of Quotient Ltd stock on 15 September 2022 worth over $140,000. On average, Heino trades about 28,704 units every 40 days since 2014. As of 31 January 2023 he still owns at least 11,582 units of Quotient Ltd stock.
You can see the complete history of Mr. Von stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Heino.N.F.M von Prondzynski biography
Heino.N.F.M von Prondzynski serves as Independent Chairman of the Board of the Company. He joined the Board as our Lead Independent Director in September 2014. Mr. von Prondzynski served as chief executive officer of Roche Diagnostics and as a member of the executive committee of F. Hoffman-La Roche Ltd., a Swiss based healthcare company that develops diagnostics and therapeutic products, from early 2000 to 2006, retiring from Roche at the end of 2006. From 1996 to 2000, Mr. von Prondzynski held several executive positions, including president of the vaccine business, at Chiron Corporation, a multinational biotechnology firm that developed biopharmaceuticals, vaccines and blood-testing products. Earlier in his career, Mr. von Prondzynski held sales and marketing and general management positions at Bayer AG, a German based maker of healthcare products, specialty materials and agricultural products. Mr. von Prondzynski also serves on the board of Epigenomics AG. Mr. von Prondzynski also has served as a director of Koninklijke Philips Electronics NV (from 2007 to 2019), Hospira, Inc. (from 2009 to 2015), Nobel Biocare Holding AG, Switzerland (from 2010 to 2011) and Qiagen NV (from 2007 to 2013). Mr. von Prondzynski studied maths, geography and history at Westfälische Wilhelms University, Münster, Germany.
What is the salary of Heino Prondzynski?
As the Independent Chairman of the Board of Quotient Ltd, the total compensation of Heino Prondzynski at Quotient Ltd is $465,440. There are 4 executives at Quotient Ltd getting paid more, with Franz Walt having the highest compensation of $2,290,340.
How old is Heino Prondzynski?
Heino Prondzynski is 70, he's been the Independent Chairman of the Board of Quotient Ltd since 2018. There are 2 older and 12 younger executives at Quotient Ltd. The oldest executive at Quotient Ltd is John Wilkerson, 77, who is the Independent Director.
What's Heino Prondzynski's mailing address?
Prondzynski's mailing address filed with the SEC is 275 N Field Dr, Lake Forest, IL 60045, USA.
Insiders trading at Quotient Ltd
Over the last 10 years, insiders at Quotient Ltd have traded over $5,237,327 worth of Quotient Ltd stock and bought 21,364,813 units worth $72,052,006 . The most active insiders traders include Advisors Llcperceptive Life..., Zubeen Shroff e L John Wilkerson. On average, Quotient Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $57,203. The most recent stock trade was executed by Catherine Larue on 31 January 2023, trading 438 units of QTNT stock currently worth $166.
What does Quotient Ltd's logo look like?
Complete history of Mr. Von stock trades at Quotient Ltd
Quotient Ltd executives and stock owners
Quotient Ltd executives and other stock owners filed with the SEC include:
-
Franz Walt,
Chief Executive Officer, Director -
Edward Farrell,
Chief Operating Officer -
Jeremy Stackawitz,
Chief Commercial Officer -
Peter Buhler,
Chief Financial Officer -
Heino.N.F.M von Prondzynski,
Independent Chairman of the Board -
Frederick Hallsworth,
Independent Director -
Brian McDonough,
Independent Director -
Zubeen Shroff,
Independent Director -
John Wilkerson,
Independent Director -
Catherine Larue,
Independent Director -
Isabelle Buckle,
Independent Director -
Ernest Larnach,
Head - Financial Accounting & Treasury -
Esteban Uriarte,
Chief Manufacturing Operations Officer -
Mohammad El Khoury,
Chief Commercial Officer -
Christian Albrich,
Chief People Officer -
Dr. Christine Ginocchio,
Chief Scientific & Medical Officer -
Dr. Michael Hausmann,
Chief Technology Officer -
Vittoria Bonasso,
Head of Fin., Group Controller & Principal Accounting Officer -
Ali Kiboro,
Chief Financial Officer -
Manuel O. Mendez,
CEO & Director -
Ernest Larnach,
Head of Financial Accounting & Treasury -
Vittoria Bonasso,
See Remarks -
Roland Boyd,
See Remarks -
Thomas A Bologna,
Director -
Sarah A Oconnor,
Director -
Stephen Unger,
Chief Financial Officer -
Partners V Lp Galen Partner...,
-
Deidre Quotient Biodiagnost...,
-
D J Paul E Cowan,
See Remarks -
Sophie Bechu,
Director -
Advisors Llcperceptive Life...,
-
Christopher J Lindop,
EVP -
Ali Kiboro,
Chief Financial Officer -
Manuel O. Mendez,
Chief Executive Officer -
Khoury Mohammad El,
Chief Commercial Officer -
Thomas Aebischer,
Director